Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841608 | 1.00 | TSHR (0.32) | TSHRTDP1HRH3HTR1ADRD2 | |
| SCHEMBL10174210 | 0.90 | FDPS (0.33) | — | |
| SCHEMBL866725 | 0.89 | KCNH2 (0.31) | — | |
| SCHEMBL12669645 | 0.88 | CYP1A2 (0.33) | TSHR | |
| SCHEMBL3217467 | 0.87 | TSHR (0.31) | TSHRTDP1 | |
| SCHEMBL20202518 | 0.84 | — | — | |
| SCHEMBL23192224 | 0.84 | ALDH1A1 (0.33) | — | |
| SCHEMBL12454224 | 0.84 | FDPS (0.33) | — | |
| SCHEMBL13293940 | 0.83 | FDPS (0.31) | — | |
| SCHEMBL25018206 | 0.83 | CA12 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229026-A1 | CHIRAL CONTROL | WAVE LIFE SCIENCES LTD. (SG) | 2024-07-11 | — | — | US | disclosed |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | WAVE LIFE SCIENCES LTD. (SG) | 2023-09-21 | — | — | US | disclosed |
| US-RE49594-E1 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2023-08-01 | — | — | US | disclosed |
| US-RE49594-E1 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2023-08-01 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11643657-B2 | Chiral control | WAVE LIFE SCIENCES LTD. (SG) | 2023-05-09 | — | — | US | disclosed |
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | RESEARCH TRIANGLE INSTITUTE (US) | 2022-12-27 | — | — | US | disclosed |
| WO-2022119645-A1 | TREATED ARTICLE, METHODS OF MAKING THE TREATED ARTICLE, AND DISPERSION FOR USE IN MAKING THE TREATED ARTICLE | AGC CHEMICALS AMERICAS, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022119644-A1 | TREATED ARTICLE, METHODS OF MAKING THE TREATED ARTICLE, AND DISPERSION FOR USE IN MAKING THE TREATED ARTICLE | AGC CHEMICALS AMERICAS, INC. (US) | 2022-06-09 | — | — | WO | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-7642361-B2 | Thiophene and furan compounds | ELI LILLY AND COMPANY (US) | 2010-01-05 | — | — | US | disclosed |
| US-7625932-B2 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY (US) | 2009-12-01 | — | — | US | disclosed |
| US-7601738-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2009-10-13 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| US-7247644-B2 | Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics | ELI LILLY AND COMPANY (US) | 2007-07-24 | — | — | US | disclosed |
| US-20070105852-A1 | Thiophene and furan compounds | ELI LILLY AND COMPANY | 2007-05-10 | — | — | US | disclosed |
| US-7205313-B2 | Excitatory amino acid receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2007-03-22 | — | — | US | disclosed |
| US-7157582-B2 | Selective iGluR5 receptor antagonists | ELI LILLY AND COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11535630-B2 | Apelin receptor (APJ) agonists and uses thereof | APLNR, AP1G1, APMAP | TSHR 169/4885TDP1 4073/4885HRH3 1113/4885 |
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | TSHR 3681/4885TDP1 649/4885HRH3 222/4885 |
| US-20240229026-A1 | CHIRAL CONTROL | RNGTT, POLI, NSUN3 | TSHR 3259/4885TDP1 924/4885HRH3 4581/4885 |
| US-20230295617-A1 | METHODS AND COMPOSITIONS OF BIOLOGICALLY ACTIVE AGENTS | ELOVL6, ELOVL5, ELOVL1 | TSHR 3764/4885TDP1 1846/4885HRH3 4845/4885 |
| US-11643657-B2 | Chiral control | RNGTT, POLI, NSUN3 | TSHR 3259/4885TDP1 924/4885HRH3 4581/4885 |
| US-20070105852-A1 | Thiophene and furan compounds | PSEN2, PSEN1, TPMT | TSHR 980/4885TDP1 287/4885HRH3 2934/4885 |
| US-20070066573-A1 | Pyrrole and pyrazole derivatives as potentiators of glutamate receptors | GRIN1, GRIN3A, GRIK5 | TSHR 315/4885TDP1 1306/4885HRH3 1043/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | TSHR 1333/4885TDP1 3813/4885HRH3 2355/4885 |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | MCL1, BCL9, BCL2L1 | TSHR 4716/4885TDP1 2735/4885HRH3 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.